UCB Pays Up to $2.2 Billion for Candid Therapeutics: Doubling Down on T-Cell Engagers in Autoimmune Disease
May 4, 2026 – 9:56 am
The Belgian pharma company UCB is acquiring the two-year-old San Diego biotech Candid Therapeutics for $2 billion upfront, representing a significant bet on T-cell engagers in autoimmune disease treatment.
The Investment Rationale
Candid Therapeutics, with its two-year history and yet to approve drug, has been testing its lead program in approximately 100 patients across multiple early-stage trials. UCB‘s investment is driven by the potential of T-cell engagers, specifically targeting B-cell killers designed for cancer applications, to revolutionize the treatment of autoimmune diseases.
Under the terms announced on May 3, UCB will pay $2 billion in upfront cash, with an additional $200 million in milestone payments contingent upon development and regulatory progress. The deal is expected to close by the end of the second quarter or early third, subject to antitrust clearance. UCB maintains its 2026 financial guidance, indicating its commitment to integrating the transaction without adjusting expectations.
A Second Bet on T-Cell Engagers
This acquisition follows UCB’s earlier licensing deal with China-based Antengene for ATG-201, a CD19/CD3 bispecific antibody, worth up to $1.1 billion. The Candid Therapeutics acquisition diversifies UCB’s portfolio by introducing a distinct B-cell target.
What Does Candid Offer?
Candid’s lead asset, cizutamig, is a bispecific antibody designed to connect T-cells and plasma cells. By targeting CD3 on T-cells and BCMA (B-cell maturation antigen) on plasma cells, it instructs the T-cells to destroy the latter, effectively depleting autoreactive B-cells and plasma cells responsible for autoimmune conditions like lupus and myasthenia gravis.
UCB reports that cizutamig has been evaluated in over 100 patients across multiple myeloma and autoimmune indications, with promising results driving Phase 1 studies in more than ten autoimmune diseases.
UCB describes cizutamig as a potential "best-in-class" BCMA T-cell engager for autoimmune disease, reflecting both ambition and industry standards for such announcements. The early data from this class of drugs has been remarkable, demonstrating durable remissions in severe cases where traditional treatments have offered only partial control.